Trastuzumab mecanismo de accion pdf merge

Pdf dual her2 targeting with trastuzumab and liposomal. Trastuzumab, a recombinant antibody targeting her2, was the first biological drug approved for the treatment of her2positive bc. Trastuzumab works by binding to the her2 receptor and slowing down cell duplication. Although there are currently other antiher2 agents available e. Adjuvant pertuzumab and trastuzumab in early her2positive. Trastuzumab 440 mg20 ml en ampula oncologia info medicamento. Trastuzumab is a humanized monoclonal antibody that targets her2.

Trastuzumab mechanism of action and use in clinical practice. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Dual her2 targeting with trastuzumab and liposomalencapsulated doxorubicin mm 302 demonstrates synergistic antitumor activity in breast and gastric cancer. In patients with her2positive metastatic breast cancer, pertuzumab added to trastuzumab and docetaxel has been shown to significantly prolong both progressionfree survival and overall survival. It consists of trastuzumab, a humanized mab directed against her2, and a microtubule inhibitor, dm1, conjugated to trastuzumab.

Iii study combining pertuzumab with trastuzumab and docetaxel in metastatic breast. Uncertainty over theoptimal duration of adjuvant trastuzumab therapy 5 july 20071extends to optimal sequencingandlongterm outcomes. Ado trastuzumab emtansine tdm1 is an antibodydrug conjugate adc approved for the treatment of her2positive metastatic breast cancer. Adotrastuzumab emtansine targets hepatocytes via human. Herceptin indicaciones, dosificacion, presentacion, efectos. Antineoplasico anticuerpo monoclonal categorias farmacologicas farmacocinetica. It is on the world health organizations list of essential medicines, the safest and most effective medicines needed in a health system. Rather than too few patients and events1, low efficacy is the likelier causeof lackingsignificant. Pdf molecular mechanisms of trastuzumab resistance in her2.